PMID- 35641154
OWN - NLM
STAT- Publisher
LR  - 20240216
IS  - 1555-3906 (Electronic)
IS  - 0965-0407 (Linking)
DP  - 2022 May 31
TI  - Long noncoding RNA TFAP2A AS1 exerts promotive effects in non small cell lung 
      cancer progression via controlling the microRNA 548a 3p/CDK4 axis.
LID - 10.3727/096504022X16540075150990 [doi]
AB  - In this study, we mainly focus on probing expression profile and detailed 
      functions of long non coding RNA TFAP2A antisense RNA 1 (TFAP2A AS1) in non small 
      cell lung cancer (NSCLC). Moreover, the mechanisms played by TFAP2A AS1 were 
      unraveled comprehensively. Herein, a notable overexpressed TFAP2A AS1 in NSCLC 
      was observed by TCGA and our own cohort. An increased TFAP2A AS1 level displayed 
      a negative correlation with the overall survival of patients with NSCLC. Loss of 
      function approaches illustrated that the absence of TFAP2A AS1 weakened NSCLC 
      cell proliferation, colony formation, migration and invasion in vitro. Also, 
      interference of TFAP2A AS1 caused in vivo tumor growth suppression. 
      Mechanistically, TFAP2A AS1 could negative regulate microRNA 584 3p (miR 584 3p) 
      as a competitive endogenous RNA. Furthermore, cyclin dependent kinase 4 (CDK4), a 
      direct target of miR 584 3p, was positively controlled by TFAP2A AS1 in a miR 
      5184 3p dependent manner. Rescue function experiments corroborated that the 
      anticancer activities of TFAP2A AS1 deficient on the oncogenicity of NSCLC cells 
      were reversed by downregulating miR 584 3p or overexpressing CDK4. To sum up, 
      TFAP2A AS1 exhibits cancer promoting roles in NSCLC through the adjustment of miR 
      584 3p/CDK4 axis.
FAU - Zhang, Yang
AU  - Zhang Y
AD  - Department of Oncology, Jilin Province Cancer Hospital, Jilin 130012, China.
FAU - Ma, Lixia
AU  - Ma L
AD  - Department of Oncology, Jilin Province Cancer Hospital, Jilin 130012, China.
FAU - Zhang, Tingting
AU  - Zhang T
AD  - Department of Oncology, Jilin Province Cancer Hospital, Jilin 130012, China.
FAU - Li, Peidong
AU  - Li P
AD  - Department of Oncology, Jilin Province Cancer Hospital, Jilin 130012, China.
FAU - Xu, Jiabin
AU  - Xu J
AD  - Department of Oncology, Jilin Province Cancer Hospital, Jilin 130012, China.
FAU - Wang, Zhuo
AU  - Wang Z
AD  - Department of Oncology, Jilin Province Cancer Hospital, Jilin 130012, China.
LA  - eng
PT  - Journal Article
DEP - 20220531
PL  - United States
TA  - Oncol Res
JT  - Oncology research
JID - 9208097
SB  - IM
EDAT- 2022/06/01 06:00
MHDA- 2022/06/01 06:00
CRDT- 2022/05/31 21:23
PHST- 2022/06/01 06:00 [pubmed]
PHST- 2022/06/01 06:00 [medline]
PHST- 2022/05/31 21:23 [entrez]
AID - 10.3727/096504022X16540075150990 [doi]
PST - aheadofprint
SO  - Oncol Res. 2022 May 31. doi: 10.3727/096504022X16540075150990.